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1. Introduction 
Radiosensitization effects of hyperthermia and chemotherapeutic agents as currently 
exploited in the clinic are discussed with respect to the linear quadratic parameters of dose-
survival curve presentations. Studies of different human tumour cell lines show that a 
synergistic interaction can be obtained between hyperthermia, chemotherapy and radiation 
and that this interaction is more likely to occur in cell lines which are relatively sensitive to 
chemotherapy. The influence of modifying agents on radiation dose survival curves can 
adequately be analysed with the use of the linear-quadratic model: S(D)/S(O)= exp-
(ǂD+ǃD2). The linear parameter, ǂ, represents lethal damage from single particle events and 
describes the low dose area while the quadratic parameter, ǃ, indicating sub lethal damage 
(SLD) dominates the effectiveness in the high dose region (Barendsen, 1990, 1994, 1997). 
The linear-quadratic model is based on well accepted biophysical concepts, involving the 
assumption that lethal damage can be induced by single-particle tracks and by interaction of 
damage from multiple particles. It has been found to describe the low-dose region of the 
survival curves up to 6 Gy rather accurately. Furthermore the LQ-model has been shown to 
describe adequately dose fractionation effects for normal tissue tolerance and for 
experimental tumours. The LQ-model has also the advantage that it requires only two 
parameters to describe radiation dose-survival curves. It allows the separate analysis of 
changes in effectiveness in the low dose range, mainly determined by the linear term and in 
the high dose range determined mainly by the quadratic term (Barendsen, 1982; Joiner & 
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Kogel, 2009). An additional advantage of the LQ model is that its parameters can be 
discussed in terms of specific mechanisms of cell inactivation by radiation (Barendsen, 1990, 
1994). Linear-quadratic analyses of hyperthermia- or chemotherapy-induced radiation 
sensitisation have been reported for exponentially growing and plateau phase human 
tumour cells in culture and for different experimental rodent cell lines (Franken et al., 1997a, 
1997b; van Bree et al., 1997, 2000; Castro Kreder et al., 2004; Bergs et al., 2006, 2007abc). 
When the additional treatment results in increases of the value of the ǂ-parameter, this 
indicates that this treatment radiosensitizes at clinically relevant doses. When the additional 
treatment influences the value of the ǃ-parameter it indicates that the additional treatment 
has an effect on the repair of sublethal damage.  
In order to determine the linear and quadratic parameters and the effects of the different 
agents on these parameters clonogenic assays (Franken et al., 2006) were conducted of cells 
after ionizing radiation only and after combined hyperthermia or chemotherapy with 
radiation treatment. Radiation dose survival curves have been obtained and analysed 
according to the LQ formula: S(D)/S(0)= exp-(ǂD+ǃD2). (Barendsen, 1982; Barendsen et al., 
2001; Franken et al., 2004, 2006). The effects of the different agents on the linear parameter, ǂ 
and quadratic parameter, ǃ will be described. If significant changes are derived, the values 
of / ratio’s are also of interest, because these ratio’s show whether the influence of the 
dose per fraction, dose fractionation and dose rate in radiation treatments is larger or 
smaller due to the combined treatments. These ratio’s may increase with increasing  or 
decreasing . A change in the / ratio might be clinically of interest for the selection of 
fractionation schedules. 
2. Hyperthermia 
Hyperthermia refers to heat treatments if cells or malignancies in which the temperature is 
elevated in the range of 39C to 45C. It is used in combination with chemo- and/or 
radiotherapy since it is has been shown to enhance the anti-cancer effects of both therapies 
(Gonzalez Gonzalez et al., 1995; Van Der Zee et al., 2002; Crezee et al. 2009). Many in vitro 
studies on the combination of hyperthermia and radiation have shown a synergistic 
interaction between the two modalities, especially at higher temperatures (above 42ºC) 
(Dewey et al., 1978; Roti Roti, 2004; Raaphorst et al., 1991). This interaction is believed to 
result from inhibition of repair of radiation-induced DNA damage by hyperthermia 
(Kampinga et al., 2001; Hildebrandt et al., 2002). The sequence of combined radiation and 
hyperthermia treatment is important. Optimal sensitization is obtained when radiation and 
hyperthermia are applied simultaneously or with a short interval (Hall & Giaccio, 2006). In 
the clinic this is not always possible. In our experiments hyperthermia was applied 
immediately after radiation treatment. 
Despite the clinical goal to reach (cytotoxic) temperatures as high as 43 ºC, tumour 
temperature distributions are in practice heterogeneous. In large areas of the tumour 
temperatures are often lower than 43ºC. Nonetheless, good results have been obtained in 
locally advanced cervical cancers with tumour temperatures below 43 ºC (van der Zee et al., 
2000). Mild temperatures have more subtle effects than high temperatures, such as tumour-
reoxygenation (Dewhirst et al., 2005; Bergs et al., 2007abc). Recently it has been shown that 
hyperthermia (42 ºC for 1h) transiently breaks down the BRCA2 protein (Krawczyk et al., 
2011). In this paragraph the effects of hyperthermia treatment for 1h at 41 or 43 C on the 
linear quadratic parameters are summarized. Several different cell types have been studied.  
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2.1 Effect of hyperthermia treatment on radiosensitivity of RKO cells  
The RKO cells, derived from human colon cancer, are relatively sensitive to hyperthermia 
treatment. Hyperthermia treatment for 1h at 43ºC decreases the relative survival to less than 
0.01 and combination with radiation doses in excess of 5 Gy always resulted in a situation in 
which no colony formation was observed. Treatment  of cells  with  41ºC  hyperthermia  (1h)  
alone  had  little  effect and resulted in a surviving fraction of 0.8 ± 0.4 in immediately plated 
(ip) cells and of 0.9 ± 0.1 in delayed plated (dp) cells. When cells were treated at 41C for 1h 
immediately prior to irradiation, a significant (p < 0.001) enhancement of cellular 
radiosensitivity was observed both in ip (figure 1A) and dp (figure 1B) cells.  
 
 
 
Fig. 1. Radiation survival curves of confluent cultures of RKO cells (human colon cancer 
cells) plated immediately after irradiation, ip (top) or 24h after irradiation, dp (below) with 
or without hyperthermia pre-treatment at 41ºC for 1h. Means with standard errors of at least 
three experiments are shown 
41°C ip 
41°C ip 
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The effects of hyperthermia on the LQ parameters are summarized in table 1. The value of 
the linear parameter ǂ increased by a factor 1.7-1.8 while the value of the ǃ parameter even 
increased with a factor as high as 2.5-7.0. One must bear in mind that the quadratic 
component in this cell line is very small and small changes can have a large effect on the 
numerical values of . 
2.2 Effect of hyperthermia treatment on radiosensitivity of SW-1573 cells 
SW-1573 cells are derived from a human lung tumour and are much less sensitive to 
hyperthermia treatment than RKO cells. Studies were performed to evaluate whether 
pretreatment with hyperthermia at 41C or at 43C in SW-1573 cells was able to enhance the 
radiosensitivity of these cells. Hyperthermia treatment at 41C for 1h without radiation did 
not result in a decrease of the surviving fraction for ip and dp cells as compared to radiation 
alone. One hour hyperthermia treatment at 43 ºC decreased survival to 0.5 ± 0.1 for ip and to 
0.4 ± 0.2 for dp cells. Pre-treatment of cells at 41C for 1h did not alter cellular 
radiosensitivity of both ip and dp cells (figure 2A). However, 1h treatment at 43C resulted 
in a significant (p < 0.001) radiation enhancement both in ip and dp cells (figure 2B). In table 
I the values of the linear-quadratic parameters for radiation alone and for combined 
treatments are given. Hyperthermia treatment for 1 h at 41C did result in an increase of the 
value of ǃ by a factor 1.3-1.8 while the value of ǂ even decreased. Hyperthermia treatment 
for 1 h at 43C result in an increase of the value of ǂ by a factor 2.3-4.4 while the value ǃ 
increased with a factor 1.8-2.0.  
 
 
 
 
Fig. 2. Radiation survival curves of confluent cultures of SW-1573 cells (human lung tumour 
cells) plated immediately after irradiation (ip) or 24h after irradiation (dp) with or without 
hyperthermia pre-treatment at 41ºC (left) or at 43ºC (right) for 1h. Means with standard 
errors of at least three experiments are shown. 
41°C ip 
41°C ip 43°C ip 
43°C ip 
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Cells Treatment ǂ (Gy-1) ǃ (Gy-2) ǂ/ǃ ǂ-enhanc 
factor 
ǃ-enhanc 
factor 
RKO ip sham 0.55  0.09 0.02  0.01 27.5  14.1   
 HT 41 1h 0.93  0.09* 0.05  0.02 18.6  7.7 1.7  0.3 2.5  1.6 
RKO dp sham 0.47  0.09 0.01  0.01 47.0  47.61   
 HT 41 1h 0.83  0.08* 0.07  0.02 11.9  3.6 1.8  0.4 7.0  7.3 
SW1573 ip sham 0.21  0.02 0.06  0.02 3.5  1.2   
 HT 41 1h 0.06  0.02 0.11  0.03 0.6  0.2 0.3  0.1 1.8  0.8 
 HT 43 1h 0.49  0.04* 0.12  0.03 4.1  1.1 2.3  0.3 2.0  0.8 
SW1573 dp sham 0.09  0.02 0.06  0.02 1.5  1.6   
 HT 41 1h 0.05  0.02 0.08  0.02 0.6  0.6 0.6  0.3 1.3  0.6 
 HT 43 1h 0.40  0.04* 0.11  0.03 3.6  1.1 4.4  1.1 1.8  0.8 
Sham= is radiation only; ip=immediately plated; dp=delayed plated. * Significant from sham p<0.05. 
1The ǂ/ǃ has a large variation because of the high uncertainty of the value of ǃ.  
Table 1. Values of the linear-quadratic parameters ǂ and ǃ, ǂ/ǃ and enhancement factors 
from cells treated with ionizing radiation only and after combined radiation and 
hyperthermia treatment 
3. Cisplatin 
Cisplatin is a widely used anti-cancer drug, often combined with radiotherapy (Gorodetsky et 
al., 1998). Chemo-radiation application based on cisplatin has now become the standard 
treatment for, among others, locally advanced cervical carcinoma (Duenas-Gonzalez et al., 
2003) and locally advanced non-small cell lung cancer (NSCLC) (Loprevite et al., 2001). 
There have been many studies on the radiation sensitizing effect of cisplatin, but results 
vary from a clear cisplatin-induced radiosensitization (Begg et al., 1986; Nakamoto et al., 
1996; Bergs et al., 2006, 2007ab) to only an additive effect on cell survival (Fehlauer et al., 
2000). Cisplatin and radiation have in common that their cellular target is DNA (Rabik & 
Dolan, 2007).  
Cisplatin causes DNA damage by the formation of inter- and intrastrand adducts (Crul et 
al., 2002). The cisplatin-DNA adducts can cause cell cycle arrest, inhibition of DNA 
replication and transcription, and eventually apoptosis (Myint et al., 2002). Repair inhibition 
of DNA has also been implicated (Lawrence et al., 2003) The most important repair 
pathways reported to be involved in cisplatin-induced DNA damage repair are nucleotide 
excision repair (NER) and/or homologous recombination (HR) (Haveman et al., 2004; De 
Silva et al., 2002). An additional route for the repair of cisplatin-DNA interstrand adducts is 
the post-replication/translation repair pathway which helps the cell to tolerate or bypass the 
lesion (Dronkert & Kanaar, 2001). Irradiation causes repairable (potentially lethal) and non-
repairable (lethal) lesions to the DNA which are induced independently. The ultimate effect 
of the repairable lesions depends on competing processes of repair and misrepair. The 
repair of the potentially lethal damage (PLDR) is reflected by the difference in survival 
between immediately and delayed plated cells. Inhibition of PLDR is implicated to play a 
role in cisplatin-induced radiation sensitization (Bergs et al., 2006). More specifically, 
cisplatin-induced radiation sensitization has been shown to occur through inhibition of the 
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non-homologous end joining (NHEJ) pathway and recombinational repair (Myint et al., 
2002; Haveman et al., 2004; Dolling et al., 1999).  
In this paragraph the radiation sensitization of cisplatin on the lung tumour cell line SW1573 
and the cervical tumour cell line Siha is described as changes in linear and quadratic 
parameters. In figure 3 survival curves are shown for SW1573 lung tumour cells after 
radiation alone and after radiation combined with cisplatin treatment (1 μM for 1 h). 
Cisplatin was added to the cultures just before radiation. The survival curves are obtained 
directly (ip) and 24 h after (dp) treatment to determine potentially lethal damage repair. A 
slight, but statistically significant effect of cisplatin on the radiosensitivity was only   
 
 
 
 
Fig. 3. Radiation survival curves of confluent cultures of SW-1573 cells plated immediately 
after irradiation, ip (top) or 24 h after irradiation, dp (below) with or without 1µM cisplatin 
treatment for one hour. Means with standard errors of at least three experiments are shown. 
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observed in delayed plated cells (p = 0.02). This was also described by an increase in the ǂ- 
and ǃ-value (table 2). Only for the delayed plated cells an increase with a factor of 2.5 for the 
value of ǂ was obtained by cisplatin treatment. For both plating conditions an increase with 
a factor of 1.2 was obtained for the value of ǃ. In the table 2 also the effects on the linear and 
quadratic parameters of different plating conditions are presented as well as a 1 h 
incubation with 1 or 5 μM cisplatin and a continuous incubation with cisplatin during the 
complete duration of the clonogenic assay. It is obvious that the cervical tumour cells Siha are 
more radiosensitzed with 1 μM continous cisplatin incubation than the SW1573 lung tumour 
cells. 
 
Cells Treatment 
ǂ (Gy-1) 
 
ǃ (Gy-2) 
 
ǂ/ǃ ǂ-enhanc 
factor 
ǃ-enhanc 
factor 
SW1573 ip sham 0.21  0.09 0.061  0.016 3.4  1.7   
 1 μM cisplatin 
(1h) 
0.21  0.08 0.072  0.018 2.9  1.3 1.0  0.6 1.2  0.4 
SW1573 dp sham 0.10  0.09 0.063  0.016 1.6  1.5   
 1 μM cisplatin 
(1h) 
0.25  0.09* 0.077  0.017 3.3  1.4 2.5  2.4 1.2  0.4 
SW1573 ppi sham 0.37  0.12 0.014 0.034 26.4  64.81   
 1 μM cisplatin 
(cont) 
0.41  0.08 0.019  0.025 21.6  28.71 1.1  0.4 1.4  3.8 
 5 μM cisplatin 
(cont) 
0.58  0.20* 0.030  0.008* 19.3  8.4 1.6  0.7 2.1  5.2 
Siha ppi sham 0.41  0.04 0.01  0.01 41.0  41.21   
 1 μM cisplatin 
(cont) 
0.81  0.12* 0.02  0.02 40.5  41.01 2.0  0.4 2.0  2.8 
Sham is radiation only; ip=immediately plated; dp=delayed plated; ppi=plated prior to irradiation. * 
Significant from sham p<0.05. / values show that with SW1573 cells the quadratic term is affected 
more than the linear term, while with Siha cells only the linear term is significantly increased.  1 The ǂ/ǃ 
has a large variation because of the high uncertainty of the value of ǃ.  
Table 2. Values of the linear-quadratic parameters ǂ and ǃ and enhancement factors from 
SW1573 and Siha cells treated with ionizing radiation only and after combined radiation 
cisplatin (1 μM for 1h; 1 μM continuously; 5 μM continuously) treatment 
4. Gemcitabine 
Gemcitabine (dFdC, Difluorodeoxycytidine) is a deoxycytidine analogue with clinical 
activity in non-small cell lung cancer (NSCLC) and pancreatic cancer (Fosella et al., 1997; 
Manegold et al., 2000; Castro Kreder et al., 2004). It requires phosphorylation to its active 
metabolites, gemcitabine-diphosphate (dF-dCTP) and gemcitabine-triphosphate (dF-dCTP), 
with the initial phophorylation by deoxycytidine kinase (dCK) being the rate limiting step 
(Heinemann et al., 1992; Shewach et al., 1994). The dF-dCTP inhibits ribonucleotide 
reductase which regulates the production of deoxynucleotides necessary for DNA synthesis 
and repair (Plukett et al., 1995). The depletion of the deoxynucleotides leads to an increased 
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incorporation of the dF-dCTP into DNA, blocking DNA synthesis (masked chain 
termination). After incorporation of the dF-dCTP into the DNA an increase in the number of 
DNA single-strand breaks, chromosome breaks and micronuclei has been observed (Auer et 
al., 1997).  
Both in vitro and in vivo studies have shown that gemcitabine is a potent radiosensitizer 
(Shewach et al., 1994; Rockwell & Grindey, 1992; Lawrence et al., 1996; Latz et al., 1998; 
Gregoire et al. 1998; Milas et al., 1999; van Putten et al., 2001, Wachters et al., 2003, Castro 
Kreder et al., 2003). However, in an early study in non-small cell lung cancer patients, 
concurrent gemcitabine and radiotherapy resulted in unacceptable pulmonary toxicity 
related to the large volume of radiation delivered to the lung (Scalliet et al., 1998). More 
recent ongoing phase I trials show that concurrent gemcitabine at lower doses and 
radiotherapy is feasible without severe pulmonary toxicity (Manegold et al., 2000; 
Blackstock et al., 2001). Its unique mechanism of action, its lack of overlapping toxicity and 
its favourable toxicity profile define gemcitabine as an ideal candidate for combination 
therapy (Manegold et al., 2000). Currently many randomized studies are ongoing in which 
gemcitabine is combined with radiotherapy. 
Gemcitabine radiosensitization is studied in a gemcitabine sensitive and resistant human 
lung tumour cells, SWp and SWg, resp., and in gemcitabine sensitive and resistant human 
ovarian tumour cells, A2780 and AG6000, resp. (Van Bree et al., 2002; Bergman et al., 2000). 
Gemcitabine was given 24 h before radiation treatment. The SWp is in fact similar to the 
SW1573 cell line which has been described above. It is called here SWp to distinguish it from 
SWg, the gemcitabine resistant counterpart which has been developed by van Bree et al. 
(2002). The lung tumour cells have different sensitivities to radiation alone as compared to 
the ovarian cancer cells (Van Bree et al., 2002; Bergman et al., 2000).  
In table 3 the linear and quadratic parameters of the different cell lines obtained after 
analyses of the radiation dose survival curves for radiation alone and after combined 
radiation and gemcitabine treatment are summarized. SWp and SWg were almost equally 
sensitive to ionizing radiation alone with respect to the low dose region described by the ǂ-
value of the linear quadratic formula (Table 3). A slight increase in survival was observed in 
SWg cells in the high dose region which was reflected by a slightly lower ǃ-value of the 
linear-quadratic formula (0.040 ± 0.006 vs 0.055 ± 0.008). The human ovarian carcinoma cell 
line A2780 and its gemcitabine-resistant variant AG6000 were equally sensitive to ionizing 
radiation. The surviving fractions of the different cell lines after incubation with gemcitabine 
alone are: SWp 10 nM: 0.52 ± 0.06; SWg 10 μM: 0.95 ± 0.03, 100 μM: 0.24 ± 0.11; A2780 2 nM: 
0.82 ± 0.08, 10 nM: 0.21 ± 0.08; AG6000 20 μM: 0.62 ± 0.07, 50 μM: 0.22 ± 0.04.  
As can be observed in figure 4 and table 3 radiosensitization is observed with gemcitabine-
sensitive as well as in gemcitabine resistant cells. For the resistant cells much higher 
gemcitabine doses are needed for the radiation sensitization to result in similar cytotoxicity. 
Both gemcitabine-sensitive cell lines SWp and A2780 are sensitized by incubation with 10 
nM of gemcitabine for 24 h before irradiation while the SWg and AG6000 are not sensitized 
with this dose of gemcitabine. The sensitization is described by an increase in the ǂ-values 
with factors of 3 and 1.4 respectively, whereas the -values are not significantly altered. 
Higher concentrations of Gemcitabine (50 and 100 nM resp.) are required to sensitize 
gemcitabine-resistant AG6000 and SWg cells to irradiation. For the SWg cells, the 
radiosensitization was reflected by an increase by a factor of 2.25 in the value of , whereas 
in the AG6000 only the ǂ-value was increased by factor of 1.3.  
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Fig. 4. Radiation sensitization after 24 h incubation with different concentrations of 
gemcitabine in gemcitabine sensitive SWp and resistant SWg lung tumour cells and in 
gemcitabine sensitive A2780 and resistant AG6000 ovary cancer cells. Surviving fractions are 
corrected for gemcitabine toxicity alone (for values see text). Cells are plated immediately 
after irradiation. Means with SEM of at least three separate experiments are shown. 
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Cells Treatment ǂ (Gy-1) ǃ (Gy-2) ǂ/ǃ ǂ -enhanc 
factor 
ǃ -enhanc 
factor 
SWp sham 0.10  0.03 0.055  0.008 1.8  0.6   
 10nM 
gemcitabine 
0.30  0.06* 0.053  0.007 5.7  1.4 3.0  2.8 0.96  0.2 
SWg sham 0.09  0.02 0.040  0.006 2.3  0.6   
 100 µM 
gemcitabine 
0.09  0.03 0.090  
0.041† 
1.0  0.6 1.0  0.5 2.3  1.1 
A2780 sham 0.80  0.10 na    
 10nM 
gemcitabine 
1.10  0.15* na  1.4  0.3  
AG6000 sham 0.83  0.13 na    
 50µM 
gemcitabine 
1.11  0.20† na  1.3  0.3  
significant difference with *P<0.01, †P<0.05, na is not applicable 
Table 3. Values of the linear-quadratic parameters ǂ and ǃ and enhancement factors from 
cells treated with ionizing radiation only and gemcitabine-sensitized radiation dose survival 
curves of gemcitabine-sensitive (SWp and A2780) and gemcitabine-resistant (SWg and 
AG6000) cells. 
5. Halogenated pyrimidines 
Incorporation of halogenated pyrimidines (HPs), chloro-, bromo- and iodo-deoxyuridine 
(CldUrd, BrdUrd, IdUrd) into DNA is known to sensitise cells to ionizing radiation (Franken 
et al. 1997ab, 1999ab; van Bree et al. 1997; Iliakis et al. 1999; Miller et al. 1992ab). The induced 
radiosensitisation increases with the degree of thymidine-replacement. The mechanism of 
radiation sensitisation by the HPs has been suggested to be either an increase in the amount 
of DNA damage induced by radiation, an influence on repair of sublethal damage (SLD), 
and/or an enhanced expression of potentially lethal damage (PLD) (Jones et al. 1995; 
Franken et al. 1997). Since different processes are involved in these phenomena several 
mechanisms might contribute to the radiosensitisation.  
HPs have been suggested to provide an advantage in radiotherapy as radiosensitisers of 
cells in rapidly growing tumours, in particular in clinical conditions in which critical normal 
tissues show limited proliferation and as a consequence take up less HP. Labelling depends 
on the growth fraction, cell loss, cell cycle time and potential doubling time. Of special 
importance for sensitisation is the rate at which non-cycling cells are recruited into the 
proliferative compartment during exposure to HPs and a course of radiotherapy. However, 
even in rapidly growing tumours, cells may, after proliferative cycles, move into a non-
proliferative stage. This might compromise the degree of radiation sensitisation if resting 
cells are less affected by HPs, or are better able to cope with additional damage by repair of 
PLD.  
Here the results of radiosensitization after incubation with 4 μM IdUrd for 72 h are 
presented. IdUrd-induced radio sensitisation was obtained in all studied cell lines, SW1573, 
RUCII (Rat urether carcinoma), R1 (Rat rhabdomyosarcoma) and V79, in exponentially 
growing and in plateau-phase cells. Values of ǂ and ǃ derived by linear-quadratic analyses 
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of survival curves of exponentially growing cells and plateau-phase cells are presented in 
table 4. Survival curves of SW cells and V79 cells are given in figure 5. The plating 
conditions of the V79 cells, i.e. exponentially growing cells plating before or after irradiation 
(ppi or dp resp.), and plateau phase cells plated immediately or 6-24 h delayed after 
irradiation (ip or dp resp.) had no influence on the factor of increase of the ǂ-value. It is 
shown that the value of the linear parameter, ǂ can be enhanced by a factor of 1.9 to 7.5 and 
that in general low values of ǂ are enhanced more than higher values of ǂ. The value of ǃ is 
less enhanced and the enhancement factor ranges from 0.7 to 2.4. 
The direct comparison between immediate and delayed plating of plateau-phase cells and 
between plateau phase and exponentially growing cells shows significant quantitative 
differences. The data on the linear and quadratic parameters described here provide 
various new insights in the interpretation of radiosensitisation of delay plated plateau-
phase cells. It is demonstrated that in delay plated HP-sensitized plateau phase cells PLD 
is not abolished. 
 
 
 
 
 
 
 
Fig. 5. Radiation dose-survival curves of exponentially growing SW-1573 cells (left) without 
IdUrd (open triangles) and after incubation with 4 M IdUrd (closed triangles) and plateau-
phase cells (right) plated immediately after irradiation (dashed lines) and plated 24 h after 
irradiation (solid lines) without IdUrd (open symbols) and after incubation with 4 M IdUrd 
(closed symbols). Each point represents the mean value of 3 different experiments  sem. 
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Cell line 
ǂ  
(Gy-1) 
control 
ǃ  
(Gy-2) 
control 
ǂ (Gy-1) 
IdUrd-
sens 
ǃ (Gy-2) 
IdUrd-
sens 
ǂ/ǃ 
control 
ǂ/ǃ 
IdUrd-
sens 
ǂ -
enhanc 
factor 
ǃ -
enhanc 
factor 
SW 1573 
cells 
Exp 
growing 
ip 
0.22 ± 0.01 0.022 ± 
0.001 
0.83 ± 0.06 na 10.0 ± 0.6 na 3.8 ± 0.3 na 
SW 1573 
cells 
Plateau 
phase ip 
0.17 ± 0.03 0.042 ± 
0.004 
0.31 ± 0.03 0.047 ± 
0.005 
4.1 ± 0.8 6.6 ± 1.0 1.8 ± 0.4 1.1 ± 0.2 
SW 1573 
cells 
Plateau 
phase dp 
0.09  0.02 0.046  
0.002 
0.37  0.04 0.033  
0.006 2.0 ± 0.4 11.2 ± 2.4 4.1 ± 1.0 0.7 ± 0.1 
RUCII 
cells Exp 
growing 
ppi 
0.008  0.007 0.025  
0.001 
0.06  0.02 0.026  
0.001 0.3 ± 0.3 2.3 ± 0.8 7.5 ± 7.0 1.0 ± 0.1 
R1 cells 
Exp 
growing 
ppi 
0.23  0.01 0.068  
0.003 
0.44  0.05 0.075  
0.016 3.4 ± 0.2 5.9 ± 1.4 1.9 ± 0.3 1.1 ± 0.2 
V79 cells 
Exp 
growing 
ip 
0.18  0.02 0.017  
0.003 
0.38  0.04 0.023  
0.007 10.6 ±2.2 16.5 ± 5.3 2.1 ± 0.3 1.4 ± 0.5 
V79 cells 
Exp 
growing 
ppi 
0.15  0.02 0.013  
0.003 
0.29  0.03 0.016  
0.004 11.5 ± 3.1 18.1 ± 4.9 1.9 ± 0.3 1.2 ± 0.4 
V 79 cells 
Plateau 
phase ip 
0.09  0.03 0.026  
0.004 
0.17  0.02 0.062  
0.005 3.5 ± 1.3 2.7 ± 0.4 1.9 ± 0.7 2.4 ± 0.4 
V 79 cells 
Plateau 
phase dp 
0.07  0.02 0.020  
0.002 
0.30  0.03 0.024  
0.004 3.5 ± 1.1 12.5 ± 2.4 4.3 ± 1.3 1.2 ± 0.2 
Means with SEM of at least three separate experiments are shown. ip=immediately plated after 
irradiation; dp=delayed plated after irradiation; ppi=plated prior to irradiation; na=not applicable. 
Table 4. Values of the linear-quadratic parameters ǂ and ǃ and enhancement factors of 
several cell lines treated with ionizing radiation only and after sensitization with 
iododeoxyuridine (incubation with 4 μM IdUrd for 72 h) 
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6. PARP-1 inhibitors 
The effect of the Parp-1 inhibitor NU-1025 on the linear and quadratic parameters was tested 
in Mouse embryonic fibroblasts. Parp1 also known as Poly (ADP-ribose) polymerase is an 
enzyme which is involved in the single strand break (SSB) repair of the DNA. The DNA SSB 
induced by ionizing radiation are mostly repaired by the base excision repair system, BER, 
wheras the DNA DSB are repaired by non homologous endjoining NHEJ or homologous 
recombination, HR. Inhibiting Parp-1 activity reduces the single strand break repair 
(Bouchard, 2003). Besides its role in BER Parp-1 is involved in many nuclear processes like 
DNA replication, transcription, DSB repair, apoptosis and genome stability (Rouleau et al. 
2010; Bouchard et al. 2003, Löser et al.  2010). Recently it was hypothesized that cells 
deficient in BRCA2 or BRCA1 are particularly sensitive to inhibition of Parp-1 (Rouleau et 
al. 2010, Krawczyck et al. 2011). During DNA replication SSBs are induced. In the absence of 
Parp-1 these SSB are transformed in DSB. These DSB are repaired with homologous 
recombination (HR). Therefore cells deficient in HR (e.g. BRCA1 or BRCA2 tumours) might 
be sensitive to Parp-1 inhibitors. As Parp-1 is involved in many DNA repair processes, Parp-
1 inhibitors might work well as radiosensitizers (Löser et al.  2010).  As can be observed in 
figure 6 a modest sensitization effect by the Parp-1 inhibitor NU-1025 was obtained and 
increase of the value of ǂ in the repair deficient cell line was larger than in the repair 
proficient cell line, 1.4 vs 1.2 respectively (table 5). The radiation dose survival curves of 
these MEF cells did not show a shoulder and therefore the quadratic parameter, ǃ, could not 
be determined. 
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Fig. 6. Radiation dose-survival curves of Mouse embryonic fibroblasts (A: LigIV+/+, 
Rad54+/+) A and LigaseIV deficient and RAD54 deficient (B: LigIV-/-, Rad54-/-) mouse 
embryonic fibroblasts. Open circles radiation only curves, closed squares:  radiation + Parp 
inhibitor. Cells were treated with 100 μM Nu-1025 for 24 h before irradiation.  
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MEF Cells Treatment with 
Parp-i 
ǂ (Gy-1) ǃ (Gy-2) ǂ -enhanc. 
factor 
LigIV+/+,Rad54+/+ No 0.28  0.01 na  
LigIV+/+,Rad54+/+ yes 0.33  0.03 na 1.2 
LigIV-/-,Rad54-/- no 1.59  0.18 na  
LigIV-/-,Rad54-/- yes 2.28  0.42 na 1.4 
Na= not applicable. 
Table 5. Values of the linear parameter, ǂ, and the enhancement factors. The quadratic 
parameter ǃ could not be determined in these MEF cells.  
7. Discussion and conclusion 
In most cases an increase of the ǂ-component was observed which corresponds to an 
enhanced (potentially) direct lethal damage (PLD) at low doses. The ǃ-component, which is 
assumed to depend on the interaction of sublethal lesions (SLD), was rarely affected by the 
studied radiosensitization agents. Moreover, it appeared that more radioresistant cell lines 
were more sensitised than the radiosensitive lines. Furthermore it can be concluded that 
radiosensitization is also dependent on cell cycle stage like plateau or exponentially growing 
phase or post treatment plating conditions. 
Hyperthermia is an excellent radiosensitizer which can already be effective at mild 
temperatures. One hour hyperthermia treatment at 41ºC without radiation had only a small 
cytotoxic effect in both the heat sensitive and the heat resistant cell line. This is in agreement 
with the general idea of cell kill induction at temperatures 42ºC for 1h or more (Dewhirst, 
2005). Hyperthermia treatment at 43ºC for 1h did not have a large cytotoxic effect in heat 
resistant SW-1573 cells. Radiosensitization by 41C temperature hyperthermia was observed 
in RKO, but not in SW-1573 cells. The ability of mild temperatures (in the range of 40-42C) 
hyperthermia to increase radiosensitivity of human tumor cells has been shown to be cell 
line dependent (Ruy et al., 1996; Franken et al., 2001; Bergs et al., 2007ab; Larsson & Ng, 
2003; Murthy et al., 1977). In a study by Xu et al. (1999) 41.1C pre-treatment of cells for 1h 
did not induce radiosensitization whereas treatment for 2h or more resulted in 
radiosensitization, in the hyperthermia resistant, but not in the hyperthermia sensitive cell 
line (Xu et al., 1999]. However, simultaneous treatment of the sensitive cell line with 1h 
41.1C hyperthermia and radiation did increase cellular radiosensitivity (Xu et al., 2002). An 
important mechanism of mild hyperthermia induced radiosensitization in vivo is the 
reoxygenation of tumors by an increase in blood flow (Vujaskovic et al., 2004; Oleson & 
Robertson, 1995; Song et al., 1995). Recently it was demonstrated that the BRCA-2 protein is 
transiently inhibited by mild hyperthermia (Krawzcyk et al., 2011). Also translocation of the 
Mre11 DSB repair protein from the nucleus to the cytoplasm has been implicated (Xu et al., 
2002, 2007). However, disappearance of Mre11 protein foci at the sites of irradiation induced 
DNA double strand breaks by 41ºC pre-incubation of cells was not observed (Krawzcyk et 
al., 2011; Bergs, 2007a). A role for mitotic catastrophe occurring as a result of G2/M 
checkpoint abrogation has also been suggested (Mackey & Ianzini, 2000). It has been shown 
that radiosensitization by 41-43C hyperthermia correlates with an increased number of 
chromosomal fragments, but not of color junctions, at 24h after treatment compared to 
radiation alone (Bergs et al., 2008).  
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It is shown that cisplatin causes radiosensitization as measured by clonogenic survival, but 
only after allowing a potentially lethal damage repair (PLDR) time of 24 hours. These results 
are in agreement with those of Wilkins et al. (1993) who investigated the effect of cisplatin 
and radiation on PLDR in confluent cultures of two different brain tumor cell lines. Wilkins 
et al. (1993) also observed no radiosensitization by cisplatin in immediately plated cells 
whereas a cisplatin-induced radiosensitization was seen in cells plated eight hours after 
irradiation. Their results indicate that the radiosensitizing effect of cisplatin occurs through 
the inhibition of post-irradiation recovery. The strongest inhibition of PLDR was achieved 
when cisplatin was administered shortly before or after irradiation (Wilkins et al., 1993). In 
our experiments, cells were irradiated while cisplatin was present in the medium. 
Results from studies using exponentially growing cell cultures vary from a cisplatin-
induced radiosensitization (Loprevite et al., 2001; Begg et al. 1986; Nakamoto et al. 1996; 
Huang et al. 2004) to only an additive effect (Gorodetsky et al., 1998; Loprevite et al., 2001; 
Britten et al., 1996; Monk et al., 2002). The effect of cisplatin treatment on radiosensitivity 
may depend on the cell type used. Loprevite et al (2001) observed synergism in a squamous 
lung carcinoma cell line when exposed to cisplatin, whereas an adenocarcinoma of the lung 
was not sensitized by cisplatin. Even cell lines derived from a single biopsy can differ in the 
response to cisplatin and radiation combination therapy (Britten et al., 1996).  
Although dependence on cell cycle phase (Meyn et al., 1980; Krishnaswamy & Dewey, 
1993), cisplatin incubation time and the sequence of treatment modalities have been 
implicated (Gorodetsky et al., 1998; Meyn et al., 1980; Krishnaswamy & Dewey, 1993), there 
is currently no consensus to account for the varying response of cells to cisplatin and 
radiation. 
The mechanism of cisplatin induced radiosensitization might be due to the inhibition of the 
DNA repair, NHEJ and HR, pathways (Myint et al., 2002; Dolling et al., 1998). The Ku 
protein complex, which plays an important role in NHEJ, was demonstrated to show a 
reduced ability to translocate on DNA containing cisplatin-DNA adducts compared with 
undamaged DNA. This resulted in a decreased interaction between Ku and DNA-PKcs 
(Turchi et al., 2000) However, the biochemical processes that cisplatin undergoes in the cell 
are complex and the intracellular fate of cisplatin may be linked to copper transport (Muffia 
& Fojo, 2004). Therefore, other processes such as the formation of peroxy complexes inside 
the cell might be involved in cisplatin-induced radiosensitization (Dewit, 1987). Bergs et al. 
(2006) demonstrated an increase in the induction of apoptosis after combined treatment as 
compared to radiation or cisplatin alone at 24 h after treatment. This was confirmed in 
several other studies (Kumala et al., 2003; Guchelaar et al. (1998). These apoptotic effects 
observed by Bergs et al. (2006) correlated with clonogenic survival. Fujita et al. (2000) also 
observed an inhibitory effect of the combination of cisplatin and radiation on the survival of 
lung tumor cells and ascribed this effect on the induction of tumor cell apoptosis.  
In conclusion, a radiosensitizing effect of cisplatin on cell survival is observed in confluent 
cultures when cells were replated after a 24 hour incubation period during which PLD 
repair could take place. In contrast, cisplatin did not induce a significant radiosensitization 
after immediate plating.  
Several studies have shown that gemcitabine is a potent sensitizer of ionizing radiation 
(Shewach et al., 1994; Gregoire et al., 1999; Ostruszka & Shewach, 2000). Among other 
proposed mechanisms of action, the effect of gemcitabine on cell cycle distributions may be 
the most important (Milas et al., 1999; Van Putten et al., 2001). In our studies, both 
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gemcitabine-sensitive cell lines SWp and A2780 could be sensitized to irradiation when 
cytotoxic gemcitabine-treatments were given. The radiosensitization was accompanied by a 
clear arrest of cells in early S phase which has been argued to be vital for gemcitabine-
induced radiosensitization (Latz et al., 1998). Both cell lines showed an increase in ǂ-value 
indicating the efficacy of gemcitabine-induced radiosensitization in the clinically relevant 
dose range. Although the gemcitabine resistant cells still could be sensitized only much 
higher gemcitabine doses were necessary to reach an effect. In the resistant ovarian 
carcinoma cell line AG6000 this was demonstrated by an increase in the value of ǂ. In 
contrast with this change, in the gemcitabine resistant lung tumour cell line an increase in 
the ǃ-value was obtained, the ǂ-value was not affected. In both gemcitabine-resistant cell 
lines the sensitivity to ionizing radiation alone was not altered. It is reported that 
gemcitabine resistant tumours are cross-resistant to related drugs like Ara-c (Ruiz van 
haperen et al., 1994; Peters et al., 1996). In both gemcitabine-resistant cell line, AG6000 and 
SWg, this was indeed the case (Van Bree et al., 2002). Moreover, the AG6000 cells were also 
more resistant to cisplatin and taxoids (Bergman et al., 2000). However, no altered 
sensitivity was found in SWg cells for cDDP, paclitaxel, MTX and 5 FU, while AG6000 cells 
were 2.5-fold more sensitive to MTX (Bergman et al., 2000). These findings indicate that 
patients previously treated with gemcitabine may receive additional radiotherapy with or 
without cDDP or paclitaxel.  
The HP-induced-radiosensitisation is mainly due to an increase in the linear parameter ǂ. 
The quadratic parameter, ǃ, is only rarely influenced. Different mechanisms involved in the 
radiosensitisation induced by halogenated pyrimidines have been described. Wang  
et al. (1994) suggested that in exponentially growing cells increased DNA damage 
production was the major component of radiosensitisation while in plateau-phase cells 
radiosensitisation occurred through inhibited repair and/or enhanced fixation of potentially 
lethal damage. The increase of the ǂ values for exponentially growing cells as found in our 
study, indicates an increase in the number of directly lethal events due to the HPs. This is in 
agreement with observations of Webb et al. (1993) and Jones et al. (1995) which suggest that 
an important mechanism of radiosensitisation involves an increase of effective DNA double 
strand breaks. Miller et al. (1992ab) have suggested that radiation-induced damage in cells 
which have HPs incorporated into the DNA after low-LET irradiation resembles the damage 
produced by high-LET radiation. In plateau-phase cells plated immediately after irradiation 
the increase of ǂ might be due to the same mechanism as involved in exponentially growing 
cells. In these cells also an increase of ǃ was observed indicating that accumulation of 
sublethal lesions contributed significantly (Barendsen 1990). Due to the immediate plating 
after irradiation this sublethal damage might be fixated.   
Greatest increases in ǂ were found in delayed plated plateau-phase cells. This 
radiosensitisation can be interpreted as an enhanced fixation of potentially lethal damage 
due to immediate DNA damage and/or to damaged DNA repair function in these cells 
expressed during the interval before delayed plating. The value of ǃ in these cells returned 
to values as found in cells not containing HPs. This demonstrates that sublethal damage has 
been repaired in HP-containing plateau-phase cells. 
Because Parp-1 is implicated in several DNA repair processes, Parp-1 inhibitors might be 
good radiosensitizers. Several studies have already demonstrated the radiosensitizing effect 
of Parp-1 inhibitors (Albert et al. 2007; Löser et al. 2010; Krawczyk et al. 2011). Loser et al 
concluded that the effects of Parp-1 inhibitors are more pronounced on rapidly dividing 
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and/or DNA repair deficient cells. In our study at time of treatment most of the cells in 
culture had accumulated in G1 phase. Therefore radiosensitization effects are modest. 
However, the increase of value of the linear parameter, ǂ, of the repair deficient cells was 
more increased after the parp-1 inhibition than of the repair proficient cells.  
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Fukushima, which taught us that the risk of ionizing radiation is closely and seriously involved in the modern
society. In this circumstance, it becomes increasingly important that more scientists, engineers and students
get familiar with ionizing radiation research regardless of the research field they are working. Based on this
idea, the book "Current Topics in Ionizing Radiation Research" was designed to overview the recent
achievements in ionizing radiation research including biological effects, medical uses and principles of
radiation measurement.
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